Study: Narcolepsy Medication Found to Improve Adult ADHD Symptoms
Alkermes' ALKS 7290, an orexin 2 receptor agonist, showed significant improvement in adult ADHD symptoms in a Phase 1B study. The drug reduced ADHD symptoms by 14-19 points and severity scores by 1-2 points. It was well-tolerated with mild side effects. Alkermes plans further trials, with results expected in 2027.
How this was made
The 30-second read
Why it matters
The data introduces a novel mechanism for ADHD treatment, potentially expanding Alkermes' pipeline and market valuation.
Market read
Early trial success may attract speculative buying in ALKS, but risk remains high until Phase 2 data.
What to watch
Potential competition from existing stimulants and regulatory hurdles for a new drug class.
Background
Alkermes announced its investigational OX2R agonist ALKS 7290 showed clinically meaningful improvements in ADHD symptoms in a double‑blind Phase 1B study.
Ticker impact
Alkermes plc disclosed Phase 1B proof-of-concept data showing ALKS 7290 improves ADHD symptoms in adults.
likely upward pressure as the market prices in potential new ADHD therapy.
Phase 1B data is a primary disclosure for a biotech; such news typically moves small‑cap stocks on expectations of future revenue.
Market effects
May broaden interest in orexin‑targeted therapies across neuro‑psychiatric drug pipelines.
Limited to US biotech sector; no broader regional effect.
Modest, confined to investors tracking early‑stage ADHD treatments.
Counterpoint
Phase 1B data is early; efficacy may not translate to later phases, and safety concerns could emerge.
Key entities
- companyAlkermes plc
Pharmaceutical company developing ALKS 7290.
- personGreg Mattingly, M.D.
Consultant on the trial, provided expert commentary.
